Meeting Coverage

Combining manual therapy with exercise enhances pain relief and disability outcomes for low back pain.

The CLL 12 study found ibrutinib improved global health/physical function without overall survival benefits in early-stage, asymptomatic CLL.

On Tuesday, January 21, 2025, Joel Gelfand, MD, will join a panel of speakers to discuss the changing landscape of psoriasis and psoriatic arthritis.

Is there a session you’d like to see Physician’s Weekly cover at Maui Derm?

On Tuesday January 21, 2025 Julie Harper, MD, will lead a discussion on clinical updates for WINLEVI (clascoterone) Cream 1%.

Luis Sumoza, MD, discusses the BRUIN CLL-321 study presented during the ASH Annual Meeting, highlighting the importance of this research and how it will impact patient care.

This year’s ASH was exceptionally busy, with overlapping sessions, including three back-to-back myeloma talks. Key studies showcased practice-changing findings.

A review of treatments for TP53m MCL found high response rates with targeted and CAR-T therapies but highlighted poor survival, urging innovative strategies.

First-line, fixed-duration ibrutinib plus venetoclax provides durable progression-free survival and overall survival for patients with CLL or SLL.

An online mindfulness-based stress reduction program reduced the symptomatic burden for patients with breast cancer, according to research from SABCS.

Using AI and remote patient monitoring technology in pain management enables ongoing real-time monitoring, facilitating personalized adjustments to therapy.

A new patient registry aims to integrate clinical and patient-reported data to improve care and guide personalized treatment in early breast cancer.

Luis Sumoza, MD, highlights the need to explain the disease, its consequences, and treatment side effects to patients, highlighting effective communication with primary care providers is crucial to ensure coordinated care.

Physician’s Weekly spoke with Richard Newcomb, MD, on the role of nurses and APs in enhancing palliative care.

Early palliative care improves transplant patients’ quality of life, especially for minoritized groups or those with high distress, suggesting targeted or clinician-led care.

iMMagine-1 phase 2 trial shows 97% response, 62% complete response in relapsed/refractory myeloma, with strong safety and promising 2026 launch.

NGS aligned with FISH for detecting HER2 status in patients with breast cancer, in addition to revealing ERBB2 mutations and nuanced alterations.

Physician’s Weekly spoke with Alexey Danilov, MD, PhD, at ASH 2024 on personalized care and prognostic insights in CLL.